# An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

> **NCT03611751** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1020 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** BMS-986165
- **OTHER:** Placebo
- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT03611751
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-26
- **Primary completion:** 2020-11-29
- **Final completion:** 2020-11-30
- **Target enrollment:** 1020 (ACTUAL)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03611751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03611751, "An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03611751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*